Essential Amino Acids and Parkinsons Disease

Parkinson's disease (PD) is characterized by the loss of dopaminergic neurons in the substantia nigra and is the second most common neurodegenerative disease in older individuals. PD may involve a variety of symptoms, but the predominant manifestation is impaired physical function, including muscle atrophy and weakness, bradykinesia, and reduced endurance. Older PD patients frequently present with, or develop, greater loss of muscle mass than expected from aging alone (sarcopenia). Sarcopenia results in inactivity, chronic inflammation, and neurodegeneration, all of which compound the loss of muscle function due to PD. L-DOPA/carbidopa is the most common drug therapy for PD and can mitigate some of the physical problems with PD, but progression of the disease usually ultimately results in severe reduction of quality of life. The metabolic basis for loss of muscle mass with sarcopenia is anabolic resistance, defined as a diminished stimulation of muscle protein synthesis by dietary protein. Reduced muscle protein synthesis in response to dietary protein consumption not only contributes to the loss of muscle mass, but also to impaired single muscle fiber function, decreased mitochondrial biogenesis, and reduced neuromuscular junction stability, all of which contribute to impaired physical function. The consequences of anabolic resistance of muscle protein in PD is often compounded by the recommendation for reduced consumption of dietary protein due to the potential interference of absorbed dietary amino acids with the transport of L-DOPA from the intestine into the blood and from the blood into the brain. We have developed an EAA-based nutritional supplement called AMS2434 designed to stimulate muscle protein synthesis in older individuals with PD and to promote dopamine production in the brain. AMS2434 is cleared rapidly from the blood after consumption, thereby minimally interfering with the transport of L-DOPA/carbidopa. In addition, AMS2434 contains tyrosine to enhance the brain production of dopamine. AMS2434 also decreases plasma tryptophan, which in turn reduces its degradation product kynurenine, which may be involved in the development of sarcopenia. We have previously shown that a 10g dose of EAAs maximally stimulates muscle protein synthesis in healthy elderly. In the current protocol we will determine if 10g of a mixture of a specifically designed mixture of EAAs (AMS2434) will robustly stimulate muscle protein synthesis in anabolic resistant individuals with Parkinson's disease. In addition, we will determine if AMS2434 stimulates brain dopamine synthesis from tyrosine.